Indeed, anti-TGF-β treatments using neutralizing antibodies, inhibitors against the TGF-β receptor, or antisense oligonucleotides to TGF-β1 halt the progression of renal fibrosis development, suggesting its fibrotic role in CKD [25]. The gene discussed is TGFB1; the disease is chronic kidney disease.